StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultNov 4, 2026, 08:41 AM

Aprea Therapeutics Reports Q3 2026 Results; Cash Runway to Q1 2028

AI Summary

Aprea Therapeutics announced its third quarter 2026 financial results, reporting an operating loss of $5.2 million and a net loss of $4.8 million, or $(0.09) per share. The company's cash and cash equivalents increased to $37.8 million as of September 30, 2026, with an expected cash runway into the first quarter of 2028. Key operational updates include the expansion of the APR-1051 Phase 1 clinical trial to nine sites and the upcoming presentation of updated interim data at the 38th EORTC-NCI-AACR Symposium.

Key Highlights

  • Aprea Therapeutics reported Q3 2026 operating loss of $5.2 million, compared to $3.1 million in Q3 2025.
  • Research and development expenses increased to $3.3 million in Q3 2026 from $1.6 million in Q3 2025.
  • General and administrative expenses were $1.8 million in Q3 2026, up from $1.5 million in Q3 2025.
  • Net loss for Q3 2026 was $4.8 million, or $(0.09) per share, compared to a net loss of $3.0 million, or $(0.47) per share, in Q3 2025.
  • Cash and cash equivalents stood at $37.8 million as of September 30, 2026, compared to $14.6 million as of December 31, 2025.
  • Company expects cash runway into Q1 2028.
  • Updated interim Phase 1 data for APR-1051 to be presented at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.